



AF/1636  
ITW

PATENT  
ATTORNEY DOCKET NO. 00786/351006

Certificate of Mailing: Date of Deposit: November 22, 2004

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Janet D'Annunzio-Ellis

Printed name of person mailing correspondence

*Janet D'Annunzio-Ellis*  
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Gary Ruvkun et al.	Art Unit:	1636
Serial No.:	09/963,693	Examiner:	S. Kaushal
Filed:	September 25, 2001	Customer No.:	21559
Title:	THERAPEUTIC AND DIAGNOSTIC TOOLS FOR IMPAIRED GLUCOSE TOLERANCE CONDITIONS		

Mail Stop AF  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed. A copy of a search report from a corresponding international application is also enclosed.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

11/26/2004 AWONDAF1 00000057 09963693

01 FC:1806


180.00 OP

This statement is being filed after the mailing of a final Office action or a Notice of Allowance, but before payment of the issue fee. I, the undersigned, hereby certify that each item of information in this statement was cited in a search report from a corresponding international application, dated November 2, 2004, which is not more than three months prior to the filing of this statement. A check for \$180.00 as set forth in 37 C.F.R. § 1.17(p) is also enclosed.

If there are any other charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 22 November 2004

  
\_\_\_\_\_  
Karen L. Elbing, Ph.D.  
Reg. No. 35,238

Clark & Elbing LLP  
101 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045



Sheet 1 of 1

SUBSTITUTE FORM PTO-1449  
(MODIFIED)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE  
STATEMENT BY APPLICANT  
(Use several sheets if necessary)

(37 C.F.R. § 1.98(b))

Attorney Docket No.

00786/351006

Serial No.

09/963,693

Applicant

Gary Ruvkun et al.

Filing Date

September 25, 2001

Group

1636

IDS Filed

November 22, 2004

## U.S. PATENT DOCUMENTS

Examiner's Initials	Document Number	Issue or Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)

## FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)

## OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

	Stern et al., "The Human GRB2 and <i>Drosophila Drk</i> Genes Can Functionally Replace the <i>Caenorhabditis elegans</i> Cell Signaling Gene <i>sem-5</i> ," <i>Mol. Biol. Cell</i> 4(11):1175-1188 (1993).
	Levitan et al., "Assessment of Normal and Mutant Human Presenilin Function in <i>Caenorhabditis elegans</i> ," <i>Proc. Natl. Acad. Sci. USA</i> 93:14940-14944 (1996).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.